Moist Exposed Burn Ointment Effectiveness for Capecitabine Associated Grade II and III Hand Foot Syndrome on Stage III Colonic
DOI:
https://doi.org/10.3889/oamjms.2021.6959Keywords:
Moist exposed burn ointment, Hand foot syndrome, Colonic adeno carcinomaAbstract
Background:Hand-foot syndrome (HFS), also known as palmoplantar erythrodysesthesia, is a common adverse effect of the fluoropyrimidine chemotherapy agent capecitabine. Hand-foot syndrome of any grade is reported to affect 43% to 71% of patients treated with single-agent capecitabine chemotherapy. Although not life-threatening, it can have adverse effects on the quality of life (QoL) and daily living activities of a patient. Sometimes the dose interruptions and reductions required after observation of HFS can also impact on dose intensity and treatment outcomes. As an option for the treatment of this case, we would reported our preliminary study of the effectiveness of moist exposed burn ointment (MEBO) for stage II and III HFS.
Methods: We will evaluate the clinical sign and symptoms of hand foot syndrome grade II and III associated with capecitabine as adjuvant chemotherapy agent on advanced stage colorectal cancer. All patients with HFS will treated with topical MEBO twice daily, the clinical improvement of the symptoms will be recorded.
Results: We reported 8 cases of grade II and III hand foot syndrome, 2 patients were grade III HFS and the others were grade II. These symptoms occurred after 2 until 3 months after capecitabine administration for locally advanced (stage III) colonic adenocarsinoma. Topical MEBO were used twice a day for 3 months, pain reduction was achieved with no capicetabine dose interruption and reduction during chemotherapy period. Allergic reaction was not found during and after MEBO application in this case.
Conclusion:Moist exposed burn ointment was an effective treatment option in managing hand foot syndrome, better option in reducing the pain without interrupting the capecitabine doses.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352(26):2696-704. https://doi.org/10.1056/nejmoa043116 PMid:15987918 DOI: https://doi.org/10.1056/NEJMoa043116
Ota M, Tatsumi K, Suwa H, Watanabe J, Watanabe K, Osada S, et al. The effect of pyridoxine for prevention of hand-foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine: A randomized study. Hepatogastroenterology. 2014;61(132):1008-13. PMid:26158157
Yap YS, Kwok LL, Syn N, Chay WY, Chia JW, Tham CK, et al. Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: A randomized clinical trial. JAMA Oncol. 2017;3(11): 1538-45. https://doi.org/10.1001/jamaoncol.2017.1269 PMid:28715540 DOI: https://doi.org/10.1001/jamaoncol.2017.1269
Zheng A, Ma H, Liu X, Huang Q, Li Z, Wang L, Zeng N, Wu B. Effects of moist exposed burn therapy and ointment (MEBT/ MEBO) on the autophagy mTOR signalling pathway in diabetic ulcer wounds. Pharm Biol. 2020;58(1):124-30. https://doi.org/10.1080/13880209.2019.1711430 PMid:31967912 DOI: https://doi.org/10.1080/13880209.2019.1711430
Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, et al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: Results of a randomized, double-blind, placebo-controlled study. J Clin Oncol. 2010;28(24):3824-9. https://doi.org/10.1200/jco.2010.29.1807 PMid:20625131 DOI: https://doi.org/10.1200/JCO.2010.29.1807
Azuma Y, Hata K, Sai K, Udagawa R, Hirakawa A, Tohkin M, et al. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer. Biol Pharm Bull. 2012;35(5):717-24. https://doi.org/10.1248/bpb.35.717 PMid:22687407 DOI: https://doi.org/10.1248/bpb.35.717
Lou Y, Wang Q, Zheng J, Hu H, Liu L, Hong D, et al. Possible pathways of capecitabine-induced hand-foot syndrome. Chem Res Toxicol. 2016;29(10):1591-601. https://doi.org/10.1021/acs.chemrestox.6b00215 PMid:27631426 DOI: https://doi.org/10.1021/acs.chemrestox.6b00215
Son HS, Lee WY, Lee WS, Yun SH, Chun HK. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. Yonsei Med J. 2009;50(6):796-802. https://doi.org/10.3349/ymj.2009.50.6.796 PMid:20046420 DOI: https://doi.org/10.3349/ymj.2009.50.6.796
Nagore E, Insa A, Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (“hand-foot”) syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1(4):225-34. https://doi.org/10.2165/00128071-200001040-00004 PMid:11702367 DOI: https://doi.org/10.2165/00128071-200001040-00004
Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intra venous 5-fluorouracil/leucovorin. Ann Oncol. 2002;13(4):566-75. https://doi.org/10.1093/annonc/mdf089 PMid:12056707 DOI: https://doi.org/10.1093/annonc/mdf089
Downloads
Published
How to Cite
License
Copyright (c) 2020 Budhi Ida Bagus, Nunik Agustriani, Rieva Ermawan, Suwardi Suwardi, Amru Sungkar, Ikhdin R. Saadhi (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0